Hypertension, hypokalemia, and left adrenal tumor mimicking primary aldosteronism in a patient with 17α-hydroxylase deficiency

Abstract

17α-hydroxylase deficiency (17OHD) is a rare disorder of secondary hypertension caused by congenital adrenal hyperplasia. In addition, co-occurrence of an adrenal tumor with 17OHD is extremely rare and easily misdiagnosed. A 33-year-old female with sicca syndrome, persistent hypertension, hypokalemia, and a left adrenal tumor was referred for confirmation of primary aldosteronism. However, the absence of secondary sexual characteristics, persistent growth beyond puberty, and laboratory data of low plasma renin activity, high aldosterone, low cortisol, low sex hormones, elevated adrenocorticotropic hormone, elevated luteinizing hormone, elevated follicle-stimulating hormone, and most importantly, decreased 17-hydroxypregnenolone, supported a diagnosis of 17OHD. We sequenced the CYP17A1 gene of the patient and her parents, which demonstrated genetic defects (D487-S,488-F489 deletion and Y329K418X). 17OHD was diagnosed. The left adrenal tumor was assessed, and a non-functional adrenal incidentaloma was confirmed; NP-59 adrenal cortical scintigraphy and adrenal venous sampling showed no functional activity and non-lateralization. Hormone replacements with estrogen, spironolactone, and prednisolone were given. The patient became more feminized and confident, and her hypertension was controlled. Early diagnosis and treatment of 17OHD not only can prevent delay development of secondary sexual characteristics but also help the patient maintain mental health and improve their quality of life. In addition, the concomitant presence of a left adrenal tumor makes misdiagnosis of a functional adenoma more likely, possibly causing unnecessary surgery and delay inappropriate treatment.

Keywords

17α-Hydroxylase Deficiency / Primary aldosteronism / Adrenal incidentaloma

References

[1] Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinology and metabolism clinics of North America. 1994; 23(2): 341-57. PMid:8070426. https://doi.org/10.1016/S0889-8529(18)30101-4

[2] Rovner DR, Conn JW, Cohen EL, et al. 17 alpha-Hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis. Acta Endocrinologica. 1979; 90(3): 490-504. PMid:218415. https://doi.org/10.1530/acta.0.0900490

[3] Hwang DY, Hung CC, Riepe FG, et al. CYP17A 1 intron mutation causing cryptic splicing in 17alpha-hydroxylase deficiency. PloS One. 2011; 6(9): e25492. PMid:21966534. https://doi.org/10.1371/journal.pone.0025492

[4] Costa-Santos M, Kater CE, Auchus RJ. Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. The Journal of Clinical Endocrinology and Metabolism. 2004; 89(1): 49-60. PMid:14715827. https://doi.org/10.1210/jc.2003-031021

[5] Bao X, Ding H, Xu Y, et al. Prevalence of common mutations in the CYP17A1 gene in Chinese Han population. Clinica chimica acta. International Journal of Clinical Chemistry. 2011; 412(13-14): 1240-3. PMid:21420394. https://doi.org/10.1016/j.cca.2011.03.019

[6] Miller WL. Disorders in the initial steps of steroid hormone synthesis. The Journal of Steroid Biochemistry and Molecular Biology. 2017; 165(Pt A): 18-37. PMid:26960203. https://doi.org/10.1016/j.jsbmb.2016.03.009

[7] Wong SL, Shu SG, Tsai CR. Seventeen alpha-hydroxylase deficiency. Journal of the Formosan Medical Association = Taiwan yi zhi. 2006; 105(2): 177-81. PMid:16477341. https://doi.org/10.1016/S0929-6646(09)60342-9

[8] Turan S, Bereket A, Güran T, et al. Puberty in a case with novel 17-hydroxylase mutation and the putative role of estrogen in development of pubic hair. European Journal of Endocrinology. 2008; 325-30 p. PMid:18996963. https://doi.org/10.1530/EJE-08-0632

[9] Yen SH, Chen HT.A Case of 17α-Hydroxylase Deficiency in Genetic Female with Normal Plasma Aldosterone Level and Rudimentary Uterus. 2002.

[10] Auchus RJ. Steroid 17-hydroxylase and 17, 20-lyase deficiencies, genetic and pharmacologic. The Journal of Steroid Biochemistry and Molecular Biology. 2017; 165(Pt A): 71-8. PMid:26862015. https://doi.org/10.1016/j.jsbmb.2016.02.002

[11] Zhang M, Sun S, Liu Y, et al. New, recurrent, and prevalent mutations: Clinical and molecular characterization of 26 Chinese patients with 17alpha-hydroxylase/17,20-lyase deficiency. The Journal of Steroid Biochemistry and Molecular Biology. 2015; 150: 11-6. PMid:25697092. https://doi.org/10.1016/j.jsbmb.2015.02.007

[12] Mantero F, Opocher G, Rocco S, et al. Long-term treatment of mineralocorticoid excess syndromes. Steroids. 1995; 60(1): 81-6. PMid:7792822. https://doi.org/10.1016/0039-128X(94)00018-8

[13] Buitenwerf E, Links TP, Kema IP, et al. Congenital adrenal hyperplasia as a cause of adrenal incidentaloma. The Netherlands journal of medicine. 2017; 75(7): 298-300. PMid: 28956783.

[14] Wagnerova H, Lazurova I, Habalova V, et al. The prevalence of 21- hydroxylase deficiency in adrenal incidentalomas - hormonal and mutation screening. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2008; 116(5): 272-5. PMid:18589890. https://doi.org/10.1055/s-2007-1004551

[15] Del MP, Bernasconi D, Bertolazzi L, et al. Increased 17 alphahydroxyprogesterone response to ACTH in silent adrenal adenoma: cause or effect? Clinical endocrinology. 1995; 42(3): 273-7. PMid:7758232. https://doi.org/10.1111/j.1365-2265.1995.tb01875.x

[16] Lee SJ, Song JE, Hwang S, et al. Untreated Congenital Adrenal Hyperplasia with 17-alpha Hydroxylase/17,20-Lyase Deficiency Presenting as Massive Adrenocortical Tumor. Endocrinology and metabolism (Seoul, Korea). 2015; 30(3): 408-13. PMid:26248854. https://doi.org/10.3803/EnM.2015.30.3.408